Mar 21, 2013, 05.01 PM | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com advised holding GlaxoSmithKline Pharmaceuticals.
Sudarshan Sukhani (more)
Technical Analyst, s2analytics.com | Capital Expertise: Equity - Technical
Sukhani told CNBC-TV18, “It is a no brainer, stick with GlaxoSmithKline Pharmaceuticals , not because it is a defensive or because it is making money but because the target for this stock on the basis of charts is Rs 2500-2600 and you have nothing to loose.”
“Suppose it goes 200 points down, that does not mean anything. The chances are it will rally back again. So you are using your own profits to cover yourself and hopefully you should get much more,” Sukhani added.
GSK had tried to sell the land parcel in 2014. But
Prabhudas Lilladher has recommended accumulate rat
The investment -- worth USD 361 million or 328 mil
GlaxoSmithKline Pharmaceuticals Ltd has informed B